This Week in BMC Cancer | GenomeWeb

This Week in BMC Cancer

Premium

In BMC Cancer this week, researchers in Mexico report that cancer-initiating cells derived from established cervical cancer cell lines contain stem cell markers and show increased resistance to radiotherapy. After culturing the cells, the researchers examined them for expression of CD34, CD49f, and CD133 antigens. They found that, when injected into mice, the cancer-initiating cells induced the development of tumors in the majority of test animals.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.